Tuesday’s 10 Worst Performers. In this article, we are going to take a look at where Merck & Co. Inc. (NYSE:MRK) stands ...

Merck inked a $2 billion licensing deal with China’s Hengrui Pharma for exclusive rights to an experimental heart disease ...

We recently published a list of 15 Best Defensive Stocks Amid Market Volatility In this article, we are going to take a look ...

The S&P 500 edged 0.2% higher on Tuesday, March 25, despite a report showing that consumer confidence fell to its lowest ...

Merck secures global rights to HRS-5346, an investigational Lp(a) inhibitor, in a deal with Hengrui Pharma worth up to $1.97 billion.

Merck (MRK) has signed a licensing agreement for a heart disease drug developed by a Chinese company in a deal worth up to $2 billion, the ...

Pfizer, Merck & Co., Inc., UnitedHealth Group, Eli Lilly and Company, and AbbVie are the five Medical stocks to watch today, according to MarketBeat’s stock screener tool. Medical stocks are shares in ...

Billionaire Ken Fisher, a prominent money manager, renowned author, and financial analyst, is the founder of Fisher Asset Management.

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Merck & Co., Inc. ("Merck" or the "Company") (NYSE: MRK) and reminds investors of the April 14, ...

A class action lawsuit is brewing against Merck & Co. over claims of securities fraud, and investors aren’t exactly raising a ...

Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects ...

The stock of Merck MRK has declined 19.2% in the past six months, losing almost $52 billion of its market value The numerous ...